Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Collagen-based biodegradable matrices for localized drug delivery More
Transdermal pain patch for the treatment of moderate to severe chronic pain. More
Adhesive Patch of 90 sq. cm. and containing as active ingredient 100 mg. of ketoprofen for the local treatment of traumatic injuries and extra-articular rheumatism More
4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Glutaminyl Cyclase (QC) is an enzyme responsible for pyroglutamate formation of beta amyloids peptides. Inhibition of QC activity can potentially act as an AD therapy or even prevention as plaque cores consist entirely of pyroglutamated beta amyloids More
This invention relates to methods for manipulating the immune system using small interfering RNA (siRNA). Potential applications include the development of organ storage/reperfusion solutions and treatments for a broad range of disease indications. More
25mg dosage strenght for the OTC market More
The University of Edinburgh has developed new methods for cleaning surgical instruments, which completely remove protein contamination, including prions - the infectious agents that cause Creutzfeldt-Jakob Disease (CJD) in humans. More
Generic dossier More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Age-related disorders (other)
- Amyotrophic lateral sclerosis
- CNS (other)
- Neurodegenerative disorders
- Neurological
- Pain
- Psychiatric
- Subarachnoid hemorrhage
- Traumatic brain injury
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us